ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0878

Absolute Lymphocyte Count Is Negatively Correlated with Atherosclerotic Cardiovascular Disease Risk Score and Red Cell Distribution Width in Psoriatic Arthritis and Increases with TNF-Inhibitor Therapy

Angela Gupta1, Sofi Damjanovska2, Alyssa Lange3, Brigid Wilson4, Taissa Bej4, Maya Mattar5, David Zidar6 and Donald Anthony7, 1(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, 2(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, OH, 3Case Western Reserve University, Cleveland, 4Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, 5Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, OH, 6Case Western Reserve University/Cleveland VA Medical Center, Cleveland, 7Case Western Reserve University/Cleveland VA Medical Center/MetroHealth Medical Center, Cleveland, OH

Meeting: ACR Convergence 2020

Keywords: Anti-TNF Drugs, Biomarkers, Cardiovascular, Disease Activity, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Absolute lymphocyte count (ALC) is a parameter that represents the number of lymphocytes (B, T, and NK cells) in the blood, and lymphopenia often accompanies rheumatologic disease. Lymphopenia, even in those without rheumatologic disease, has been associated with worse survival due to cardiovascular disease (CVD), especially when accompanied by other pro-inflammatory surrogates, including increased red cell distribution width (RDW). The connection between rheumatic disease and increased risk of atherosclerotic disease has been established, but there is lack of data on ALC levels in patients with psoriatic arthritis. We sought to test the hypothesis that alterations in immunohematologic abnormalities in the setting of psoriatic arthritis may in part reflect traditional cardiovascular risk factors, but are also driven by inflammation.

Methods: We performed a retrospective chart review study examining the relationship between ALC, RDW, and traditional atherosclerotic cardiovascular disease (ASCVD) risk in a cohort (n=170) of patients with psoriatic arthritis at the Louis Stokes Cleveland VA Medical Center. All patients had an ICD-10 diagnosis of psoriatic arthritis and either a rheumatologist confirmed diagnosis of psoriatic arthritis or met CASPAR criteria. ASCVD risk was quantified using the pooled cohort equation risk model (based on age, gender, race, presence of hypertension or diabetes, lipid profile, and smoking status). We examined patient treatment history and recorded laboratory values in relation to treatment to understand the effect of immunomodulation on these parameters. The Wilcoxon signed-rank test was used for statistical analysis.

Results: ALC was negatively correlated with ASCVD score (r=-0.28, p=0.001) (Figure 1). Positive correlations were observed between ASCVD score and RDW (r= 0.339, p=0.01), ASCVD score and ESR (r=0.20, p=.02), and negative correlations were observed between ASCVD score and albumin (r=-.20, p=.01), and ASCVD score and hemoglobin (r=-.22, p=.009). When evaluating parameters over the course of therapy, those who were started on TNF-inhibitor therapy (n=60) had an increase in ALC between time 0 and 6 months (p = 0.007), and this was maintained at twelve months (p = 0.032) (Figure 2). Patients on TNF-inhibitor therapy also experienced a decline in RDW at 6 months (p = 0.004) and at 12 months (p = 0.014) (Figure 3).

Conclusion: Our data shows that abnormal lymphocyte levels and RDW are associated with traditional cardiovascular risk factors but also tend to revert with anti-TNF therapy. Thus, correlates of immunohematologic dysfunction relevant to CVD risk may be dynamic and modified by reducing inflammation, at least in psoriatic arthritis. Future studies to define whether trajectories of ALC or RDW can improve cardiovascular disease risk stratification both in psoriatic arthritis and in the general population are warranted.

Figure 1: There was a negative, statistically significant, correlation between ALC and ASCVD risk score. As ASCVD score increased, ALC value decreased.

Figure 2: Patients on TNF-inhibitor therapy exhibited a statistically significant increase in ALC over the course of 12 months.

Figure 3: Patients on TNF-inhibitor therapy exhibited a statistically significant decline in RDW over the course of 12 months.


Disclosure: A. Gupta, None; S. Damjanovska, None; A. Lange, None; B. Wilson, None; T. Bej, None; M. Mattar, None; D. Zidar, None; D. Anthony, None.

To cite this abstract in AMA style:

Gupta A, Damjanovska S, Lange A, Wilson B, Bej T, Mattar M, Zidar D, Anthony D. Absolute Lymphocyte Count Is Negatively Correlated with Atherosclerotic Cardiovascular Disease Risk Score and Red Cell Distribution Width in Psoriatic Arthritis and Increases with TNF-Inhibitor Therapy [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/absolute-lymphocyte-count-is-negatively-correlated-with-atherosclerotic-cardiovascular-disease-risk-score-and-red-cell-distribution-width-in-psoriatic-arthritis-and-increases-with-tnf-inhibitor-therap/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/absolute-lymphocyte-count-is-negatively-correlated-with-atherosclerotic-cardiovascular-disease-risk-score-and-red-cell-distribution-width-in-psoriatic-arthritis-and-increases-with-tnf-inhibitor-therap/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology